Last updated 2026-06-18
- Raised $215M funding round led by Koch Disruptive Technologies, Oct 2021
- Acquired Nebion, Aug 2021
- Acquired Dropprint Genomics, Mar 2021
Total raised
$295.0M
Last: 2021-10
Stage
Series B
Founded
2019
Headcount
192
HQ
Tel Aviv-Yafo, Israel
Sector
Health Tech & Life Sciences
About
Immunai is developing a proprietary data set of multi-omic, immune-centric peripheral tissue analyses. The company's advanced analytics and data-visualization interface allows researchers to comprehensively view and interrogate data and to derive novel conclusions on the underlying mechanisms of disease.
The platform is currently being used to develop and refine cell therapies for neuroblastoma in conjunction with the Baylor College of Medicine.
Funding history · 3 rounds · $295.0M total
2021-10
2021-02
2020-05
Q&A
- What is Immunai's primary focus?
- Immunai is developing a proprietary data set of multi-omic, immune-centric peripheral tissue analyses. Its platform is currently used to develop and refine cell therapies for neuroblastoma in conjunction with the Baylor College of Medicine.
- When was Immunai founded?
- Immunai was founded in January 2019.
- What was Immunai's most recent funding round?
- In October 2021, Immunai raised $215 million in a funding round led by Koch Disruptive Technologies.
- What was Immunai's second funding round?
- In February 2021, Immunai raised $60 million in a funding round.
- What was Immunai's first recorded funding round?
- In May 2020, Immunai raised $20 million in a funding round led by TLV Partners.
- What is the total amount of funding Immunai has raised to date?
- Immunai has raised a total of $295 million in funding.
- Which companies has Immunai acquired?
- Immunai acquired Dropprint Genomics in March 2021 and Nebion in August 2021.
- What is Immunai's primary sector?
- Immunai's primary sector is Health Tech & Life Sciences.
- Who are the co-founders of Immunai?
- The co-founders of Immunai are Noam Solomon (Co-founder & CEO), Luis Voloch (Co-founder & CTO), and Ansuman Satpathy (Scientific Co-Founder).
Team · 3
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Business SoftwareIT, R&D & Data SolutionsData Analysis & Decision SupportHealth Tech & Life SciencesDigital HealthcareMedical Decision SupportPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
Artificial IntelligenceDeep LearningMachine Learning
Target customers
Healthcare & Life SciencesHealthcareLaboratoriesProvidersLife SciencesPharmaceuticals
Business model
B2B
Tags
clinical-trialsimmunotherapyunicorn-2021digital-healthcarehospitalsimmunologydata-analyticsactionable-insightspharma-companiescancerautoimmune-diseasesartificial-intelligencemachine-learningdeep-learningcells
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | immunai.com |
|---|---|
| linkedin.com/company/53085519 | |
| YouTube | youtube.com/channel/UChTYZlcgoung0EZlsgq-G6g |
| Wikidata | wikidata.org/wiki/Q107519302 |
Identifiers & details
| Founded | 2019-1 |
|---|---|
| Employees (exact) | 192 |
| Offices | New York |
| Wikidata QID | Q107519302 |
Acquisitions & public offerings
| Acquired | Date | Amount |
|---|---|---|
| Nebion | 2021-08 | |
| Dropprint Genomics | 2021-03 |
Radar intelligence
Patents
| EPO | 4 |
|---|
Publications (Crossref)
| Works | 10 |
|---|
Web history (Wayback)
| Domain | immunai.com |
|---|
Wikidata
| QID | Q107519302 |
|---|
Certificate / subdomain footprint
| Subdomains | 12 |
|---|